ALKERMES | ALKS - Operating Expenses


ALKERMES reported $1.81B in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 1000K Jun/2026
Acadia Pharmaceuticals USD 272.68M 6.08M Mar/2026
ALKERMES USD 1.81B 57.02M Jun/2026
Amgen USD 4.78B 1.12B Mar/2026
Biogen USD 2.98B 1.02B Jun/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Eli Lilly USD 10.02B 285M Mar/2026
Gilead Sciences USD 23.52B 18.55B Mar/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
J&J USD 17.83B 388M Jun/2026
Malin Corporation EUR 1.1M 400K Dec/2024
Merck USD 18.17B 8.01B Mar/2026
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Neurocrine Biosciences USD 739.1M 139.2M Jun/2026
Otsuka Holdings JPY 561.64B 49.51B Jun/2026
Ovoca Bio EUR 173K 990K Dec/2025
Pfizer USD 85.19B 4.91B Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026